Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2024 adjusted earnings per share of $4.76, which beat the Zacks Consensus Estimate of$4.10. Earnings increased 56% year over year, driven by higher product revenues, lower costs and a lower tax rate in the quarter. The company reported total revenues of $2.69 billion, comprising cystic fibrosis (CF) product revenues. The figure beat the Zacks Consensus Estimate of$2.56 billion. Total revenues rose 13% year over year, primarily driven by hig ...